Akcay T, Fernandez-Cancio M, Turan S, Güran T, Audi L, Bereket A
Division of Pediatric Endocrinology, Department of Pediatrics, Marmara University School of Medicine, İstanbul, Turkey.
Andrology. 2014 Jul;2(4):572-8. doi: 10.1111/j.2047-2927.2014.00215.x. Epub 2014 Apr 16.
46,XY disorders of sex development (DSD) are caused by disorders of gonadal development, androgen biosynthesis and receptor (AR) defects. Although, clinical/biochemical features help in distinguishing specific aetiologies, there are overlaps which necessitate molecular analyses for the definitive diagnosis. To test precision of our clinical diagnosis of androgen insensitivity (AIS) by analysing AR and then SRD5A2 genes, patients were recruited at Marmara University Hospital and molecular analyses were performed at Vall d'Hebron Research Institute. Among 101 46,XY DSD patients, 46 index and five siblings (nine complete, 42 partial) with clinical/biochemical data suggestive of AIS and stimulated T/DHT ratio <25 were selected. AR and then SRD5A2 genes were sequenced. We detected AR mutations in 11 patients [seven index and four siblings (22% of all and 15% of index patients)] and SRD5A2 mutations in six [five index and one sibling (12% of all and 11% of index)]. AR mutation detection rate was 6/9 in all CAIS and 4/7 in the index (67 and 57% respectively) and 5/42 in all PAIS and 3/40 in the index (12 and 7.5% respectively). The eight mutations detected in the AR gene were as follows: p.Q58L, p.P392S, p.R609K, p.R775H, p.R856H, p.A871A, p.V890M and p.F892L, with p.A871A and p.F892L being novel. Further six patients had SRD5A2 mutations which were as follows: p.L73WfsX59, p.Y91H, p.R171S and p.G196S, the first being novel. Hormonal data in those with AR mutations, SRD5A2 mutations and no mutations were not statistically different. In conclusion, a significant proportion of children with presumptive diagnosis of AIS has a normal AR gene. The less severe the phenotype, the less likely is the chance of demonstrating a mutation. Furthermore, a significant number of children with presumptive diagnosis of AIS have mutations in SRD5A2 gene and are clinically and biochemically indistinguishable from AIS.
46,XY性发育障碍(DSD)是由性腺发育障碍、雄激素生物合成和受体(AR)缺陷引起的。尽管临床/生化特征有助于区分特定病因,但仍存在重叠情况,这就需要进行分子分析以明确诊断。为了通过分析AR基因然后是SRD5A2基因来检验我们对雄激素不敏感(AIS)临床诊断的准确性,在马尔马拉大学医院招募患者,并在比埃斯医院研究所进行分子分析。在101例46,XY DSD患者中,选择了46例索引患者和5例同胞(9例完全型、42例部分型),其临床/生化数据提示AIS且刺激后的T/DHT比值<25。先对AR基因进行测序,然后对SRD5A2基因进行测序。我们在11例患者中检测到AR突变[7例索引患者和4例同胞(占所有患者的22%,索引患者的15%)],在6例患者中检测到SRD5A2突变[5例索引患者和1例同胞(占所有患者的12%,索引患者的11%)]。在所有完全型雄激素不敏感综合征(CAIS)患者中AR突变检出率为6/9,在索引患者中为4/7(分别为67%和57%);在所有部分型雄激素不敏感综合征(PAIS)患者中为5/42,在索引患者中为3/40(分别为12%和7.5%)。在AR基因中检测到的8个突变如下:p.Q58L、p.P392S、p.R609K、p.R775H、p.R856H、p.A871A、p.V890M和p.F892L,其中p.A871A和p.F892L是新发现的突变。另外6例患者有SRD5A2突变,如下:p.L73WfsX59、p.Y91H、p.R171S和p.G196S,第一个是新发现的突变。有AR突变、SRD5A2突变和无突变患者的激素数据无统计学差异。总之,很大一部分初步诊断为AIS的儿童AR基因正常。表型越不严重,发现突变的可能性越小。此外,很大一部分初步诊断为AIS的儿童SRD5A2基因有突变,在临床和生化方面与AIS无法区分。